Literature DB >> 2461693

Polyneuropathies associated with IgM monoclonal gammopathies.

J J Kelly1, L S Adelman, E Berkman, I Bhan.   

Abstract

We studied ten patients with IgM monoclonal gammopathies. Five had M proteins that reacted with myelin-associated glycoprotein (MAG) and five had no recognizable antinerve activity. The neuropathy in the MAG-reactive patients was homogeneous by clinical and laboratory analysis, while the neuropathy in the MAG-nonreactive patients varied considerably. Both groups responded well to immunosuppressive therapy, which lowered the concentration of the serum M protein. The homogeneity of the MAG-reactive patients and their response to sustained lowering of the M protein levels support the concept that the IgM M protein directly damages nerve fibers and is the proximate cause of the polyneuropathy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461693     DOI: 10.1001/archneur.1988.00520360073015

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  9 in total

Review 1.  Treatment of chronic inflammatory demyelinating polyneuropathy.

Authors:  G Comi; L Roveri
Journal:  Ital J Neurol Sci       Date:  1998-10

2.  Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.

Authors:  H C Wilson; M P Lunn; S Schey; R A Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

Review 3.  Diagnosis and treatment of chronic acquired demyelinating polyneuropathies.

Authors:  Norman Latov
Journal:  Nat Rev Neurol       Date:  2014-07-01       Impact factor: 42.937

Review 4.  Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.

Authors:  Michael Pt Lunn; Eduardo Nobile-Orazio
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04

Review 5.  Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases.

Authors:  E Ellie; A Vital; A Steck; J M Boiron; C Vital; J Julien
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

6.  Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy.

Authors:  J H Ernerudh; M Vrethem; O Andersen; C Lindberg; G Berlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

7.  IgG monoclonal paraproteinaemia and peripheral neuropathy.

Authors:  A F Bleasel; S H Hawke; J D Pollard; J G McLeod
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

8.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

9.  Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study.

Authors:  Pascal Hänggi; Butrint Aliu; Kea Martin; Ruben Herrendorff; Andreas Johann Steck
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.